AZN Astrazeneca Plc

By Carlo Martuscelli

AstraZeneca PLC (AZN.LN) reported negative results from a phase 3 trial of its cancer drug Imfinzi on Friday.

The company said the Mystic trial, which examined Imfinzi as a treatment for previously untreated patients with metastatic nonsmall-cell lung cancer, didn't meet its primary objective. Patients being treated with either Imfinzi alone, or the drug plus tremelimumab, didn't demonstrate a statistically significant improvement in overall survival when compared with platinum-based chemotherapy, it said.

Imfinzi is approved as a treatment for inoperable stage 3 nonsmall-cell lung cancer in more than 40 countries. It's currently being tested in a number of phase 3 trials as a treatment for stage 4 nonsmall-cell lung cancer, the Anglo-Swedish pharmaceutical company said.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

(END) Dow Jones Newswires

November 16, 2018 02:30 ET (07:30 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.